Hope, W.; Johnstone, G.; Cicconi, S.; Felton, T.; Goodwin, J.; Whalley, S.; Santoyo-Castelazo, A.; Ramos-Martin, V.; Lestner, J.; Credidio, L.; Dane, A.; Carr, D. F; Pirmohamed, M.; Salim, R. and Neely, M.Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. In Antimicrobial Agents and Chemotherapy, 2019.doi
2018
Louie, A.; Duncanson, B.; Myrick, J.; Maynard, M.; Nole, J.; Brown, D.; Schmidt, S.; Neely, M.; Scanga, C A; Peloquin, C. and Drusano, G.L.Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model. In Antimicrobial Agents and Chemotherapy, 62 (12): 1951, 2018.doi
Drusano, G.L.; Neely, M N; Yamada, W M; Duncanson, B.; Brown, D.; Maynard, M.; Vicchiarelli, M. and Louie, A.The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model. In Antimicrobial Agents and Chemotherapy, 62 (12): 5602, 2018.doi
Neely, M.; Bayard, D.; Desai, A.; Kovanda, L. and Edginton, A.Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology. In Journal of Clinical Pharmacology, 58 Suppl 10 (2): S73-S85, 2018.doi
Drusano, G.L.; Myrick, J.; Maynard, M.; Nole, J.; Duncanson, B.; Brown, D.; Schmidt, S.; Neely, M.; Scanga, C A; Peloquin, C. and Louie, A.Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model. In Antimicrobial Agents and Chemotherapy, 62 (8): 2223, 2018.doi
Philippe, M.; Neely, M.; Rushing, T.; Bertrand, Y.; Bleyzac, N. and Goutelle, S.Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. In Bone Marrow Transplantation, 309: 1-10, 2018.doi
Alsultan, A.; Abouelkheir, M.; Elsharawy, Y.; Alkoraishi, A.; Osman, R.; Neely, M. N; Mansy, W. and Algahtani, S.Optimizing Gentamicin Dosing in Pediatrics Using Monte Carlo Simulations. In Pediatric Infectious Disease Journal: 1, 2018.doi
Jumah, M. T. B.; Vasoo, S.; Menon, S. R; De, P. P.; Neely, M. and Teng, C. BPharmacokinetic/Pharmacodynamic Determinants of Vancomycin Efficacy in Enterococcal Bacteremia. In Antimicrobial Agents and Chemotherapy, 62 (3): S4, 2018.doi
Jelliffe, R. and Bayard, D.New Perspectives in Clinical Pharmacokinetics-1: the Importance of Updating the Teaching in Pharmacokinetics that both Clearance and Elimination Rate Constant Approaches Are Mathematically Proven Equally Valid. In The AAPS Journal, 20 (2): 36, 2018.doi
Glerum, P. J; Yu, Y.; Yamada, W. M; Neely, M. N; Maliepaard, M.; Burger, D. M and Neef, C.Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs. In Clinical Pharmacology and Therapeutics, 29: 875-8, 2018.doi
Neely, M. N; Kato, L.; Youn, G.; Kraler, L.; Bayard, D.; Van Guilder, M.; Schumitzky, A.; Yamada, W.; Jones, B. and Minejima, E.Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing. In Antimicrobial Agents and Chemotherapy, 62 (2): e02042-17, 2018.doi
2017
Ramos-Mart'in, V; Johnson, A; McEntee, L; Farrington, N; Padmore, K; Cojutti, P; Pea, F; Neely, M N and Hope, W WPharmacodynamics of teicoplanin against MRSA. In Journal of Antimicrobial Chemotherapy, 72 (12): 3382-3389, 2017.doi
Sheng, X.; Parmentier, J-H.; Tucci, J.; Pei, H.; Cortez-Toledo, O.; Dieli-Conwright, C. M; Oberley, M. J; Neely, M.; Orgel, E.; Louie, S. G and Mittelman, S. DAdipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin. In Molecular cancer research : MCR, 15 (12): 1704-1713, 2017.doi
Brown, A. N; Liu, L.; Rodriquez, J. L; Zhao, L.; Schuster, L.; Li, E.; Wang, G. P; Neely, M. N; Yamada, W. and Drusano, G. LSofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). In Scientific reports, 7 (1): 14421, 2017.doi
Ramos-Mart'in, V; Neely, M N; Padmore, K; Peak, M; Beresford, M W; Turner, M A; Paulus, S; L'opez-Herce, J and Hope, W WTools for the Individualized Therapy of Teicoplanin for Neonates and Children. In Antimicrobial Agents and Chemotherapy, 61 (10): e00707-17, 2017.doi
Kovanda, L. L; Kolamunnage-Dona, R.; Neely, M.; Maertens, J.; Lee, M. and Hope, W. WPharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. In Clinical Infectious Diseases, 64 (11): 1557-1563, 2017.doi
Chen, C.; Gribble, M. O; Bartroff, J.; Bay, S. M and Goldstein, L.The Sequential Probability Ratio Test: An efficient alternative to exact binomial testing for Clean Water Act 303(d) evaluation. In Journal of environmental management, 192: 89-93, 2017.doi
Philippe, M.; Neely, M.; Bertrand, Y.; Bleyzac, N. and Goutelle, S.A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics. In Clinical Pharmacokinetics, 56 (4): 435-447, 2017.doi
Bayard, D. S. and Neely, M.Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole. In Journal of Pharmacokinetics and Pharmacodynamics, 44 (2): 95-111, 2017.doi
Jelliffe, R. WAuthor's Reply to Proost: "Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients". In Clinical Pharmacokinetics, 56 (3): 313-316, 2017.doi
Such'ankov'a, H.; Lipv s, M.; Urb'anek, K.; Neely, M. N and Strojil, J.Is continuous infusion of imipenem always the best choice?. In International Journal of Antimicrobial Agents, 49 (3): 348-354, 2017.doi
Darwich, A. S; Ogungbenro, K.; Vinks, A. A; Powell, J R.; Reny, J-L.; Marsousi, N.; Daali, Y.; Fairman, D.; Cook, J.; Lesko, L. J; McCune, J. S; Knibbe, C. A J; de Wildt, S. N; Leeder, J S.; Neely, M.; Zuppa, A. F; Vicini, P.; Aarons, L.; Johnson, T. N; Boiani, J. and Rostami-Hodjegan, A.Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. In Clinical Pharmacology and Therapeutics: 1-35, 2017.doi
Woillard, J-B.; Mourad, M.; Neely, M.; Capron, A.; van Schaik, R. H; van Gelder, T.; Lloberas, N.; Hesselink, D. A; Marquet, P.; Haufroid, V. and Elens, L.Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. In Frontiers in Pharmacology, 8: 358, 2017.doi
Shafrin, J.; Sullivan, J.; Chou, J. W; Neely, M. N; Doan, J. F and Maclean, J R.The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma. In Cancer management and research, 9: 731-739, 2017.doi
2016
Anand, V.; Holmen, J.; Neely, M.; Pannaraj, P. S and Dien Bard, J.Closing the Brief Case: Neonatal Meningitis Caused by Listeria monocytogenes Diagnosed by Multiplex Molecular Panel. In Journal of Clincal Microbiology, 54 (12): 3075-3075, 2016.doi
Burris, J. F; Tortorici, M. A; Mandic, M.; Neely, M. and Reed, M. DDosage Adjustments Related to Young or Old Age and Organ Impairment. In Journal of Clinical Pharmacology, 56 (12): 1461-1473, 2016.doi
Anand, V.; Holmen, J.; Neely, M.; Pannaraj, P. S and Dien Bard, J.The Brief Case: Neonatal Meningitis Caused by Listeria monocytogenes Diagnosed by Multiplex Molecular Panel. In Journal of Clincal Microbiology, 54 (12): 2846-2849, 2016.doi
Ramos-Mart'in, V; Neely, M N; McGowan, P; Siner, S; Padmore, K; Peak, M; Beresford, M W; Turner, M A; Paulus, S and Hope, W WPopulation pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. In Journal of Antimicrobial Chemotherapy, 71 (11): 3168-3178, 2016.doi
Mathew, S. K; Mathew, B. S; Neely, M. N; Naik, G. S; Prabha, R.; Jacob, G. G; K, S. and Fleming, D. HA Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients. In Therapeutic drug monitoring, 38 (5): 593-599, 2016.doi
Rhodes, N. J; Prozialeck, W. C; Lodise, T. P; Venkatesan, N.; O'Donnell, J N.; Pais, G.; Cluff, C.; Lamar, P. C; Neely, M. N; Gulati, A. and Scheetz, M. HEvaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. In Antimicrobial Agents and Chemotherapy, 60 (10): 5742-5751, 2016.doi
Hope, W. W; Walsh, T. J; Goodwin, J.; Peloquin, C. A; Howard, A.; Kurtzberg, J.; Mendizabal, A.; Confer, D. L; Bulitta, J.; Baden, L. R.; Neely, M. N; Wingard, J. R; lood, and Network, M. T. C. T.Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. In Journal of Antimicrobial Chemotherapy, 71 (8): 2234-2240, 2016.doi
Neely, M.; Philippe, M.; Rushing, T.; Fu, X.; Van Guilder, M.; Bayard, D.; Schumitzky, A.; Bleyzac, N. and Goutelle, S.Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the Bestdose software. In Therapeutic drug monitoring, 38 (3): 332-342, 2016.doi
Jelliffe, R. WAuthor's reply to Veloso HH Comment on "The Role of Digitalis Pharmacokinetics in Converting Atrial Fibrillation and Flutter to Sinus Rhythm". In Clinical Pharmacokinetics, 55 (5): 637-639, 2016.doi
Cattaneo, D.; Alffenaar, J-W. and Neely, M.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. In Expert Opinion on Drug Metabolism & Toxicology, 12 (5): 533-544, 2016.doi
Huurneman, L. J; Neely, M.; Veringa, A.; P'erez, F. D.; Ramos-Martin, V.; Tissing, W. J; Alffenaar, J-W. C and Hope, W.Pharmacodynamics of Voriconazole in Children: Further Steps Along the Path to True Individualized Therapy. In Antimicrobial Agents and Chemotherapy: AAC.03023-15, 2016.doi
Billat, P-A.; Woillard, J-B.; Essig, M.; Sauvage, F. c-L.; Picard, N.; Alain, S.; Neely, M.; Marquet, P. and Saint-Marcoux, F.Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. In Journal of Antimicrobial Chemotherapy, 71 (2): 484-489, 2016.doi
Neely, M.; Philippe, M.; Rushing, T.; Fu, X.; Van Guilder, M.; Bayard, D.; Schumitzky, A.; Bleyzac, N. and Goutelle, S.Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software. In Therapeutic drug monitoring: 1, 2016.doi
Picard, N; Alain, S and Neely, MPlasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. In Journal of ldots, 2016.
Rhodes, N J; Kuti, J L; Nicolau, D P and Neely, M NAn exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. In Journal of Infection and ldots, 2016.
2015
Storset, E.; AAsberg, A.; Skauby, M.; Neely, M.; Bergan, S.; Bremer, S. and Midtvedt, K.Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. In Transplantation, 99 (10): 2158-2166, 2015.doi
Kryshchenko, A.; Schumitzky, A.; van Guilder, M. and Neely, M.Nonparametric estimation of a mixing distribution for a family of linear stochastic dynamical systems. In arXiv.org, 2015.
Lalande, L; Bourguignon, L; Bihari, S; Maire, P.; Neely, M; Jelliffe, R. and Goutelle, SPopulation Modeling and Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Isoniazid in Lungs. In Antimicrobial Agents and Chemotherapy, 59 (9): 5181-5189, 2015.doi
Rhodes, N. J; Gardiner, B. J; Neely, M. N; Grayson, M L.; Ellis, A. G; Lawrentschuk, N.; Frauman, A. G; Maxwell, K. M; Zembower, T. R and Scheetz, M. HOptimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. In Journal of Antimicrobial Chemotherapy, 70 (7): 2068-2073, 2015.doi
Jelliffe, R. W; Schumitzky, A.; Bayard, D.; Fu, X. and Neely, M.Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance. In Therapeutic drug monitoring, 37 (3): 389-394, 2015.doi
Neely, M.; Margol, A.; Fu, X.; Van Guilder, M.; Bayard, D.; Schumitzky, A.; Orbach, R.; Liu, S.; Louie, S. and Hope, W.Achieving target voriconazole concentrations more accurately in children and adolescents. In Antimicrobial Agents and Chemotherapy, 59 (6): 3090-3097, 2015.doi
Glatard, A.; Bourguignon, L.; Jelliffe, R. W; Maire, P.; Neely, M. N and Goutelle, S.Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients. In Antimicrobial Agents and Chemotherapy, 2015.doi
Neely, M.; Louie, S.; Xu, J.; Anthony, P.; Thuvamontolrat, K.; Mordwinkin, N. and Kovacs, A.Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.doiwww
Rhodes, N. J; Kuti, J. L; Nicolau, D. P; Van Wart, S.; Nicasio, A. M; Liu, J.; Lee, B. J; Neely, M. N and Scheetz, M. HDefining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. In Antimicrobial Agents and Chemotherapy, 60 (3): 1401-1410, 2015.doi
2014
Frymoyer, A.; Hersh, A. L; El-Komy, M. H; Gaskari, S.; Su, F.; Drover, D. R and Van Meurs, K.Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates. In Antimicrobial Agents and Chemotherapy, 58 (11): 6454-6461, 2014.doi
Louie, A.; Liu, W.; Vanguilder, M.; Neely, M. N; Schumitzky, A.; Jelliffe, R.; Fikes, S.; Kurhanewicz, S.; Robbins, N.; Brown, D.; Baluya, D. and Drusano, G. LCombination Treatment With Meropenem Plus Levofloxacin Is Synergistic Against Pseudomonas aeruginosa Infection in a Murine Model of Pneumonia. In Journal of Infectious Diseases, 211 (8): 1326-1333, 2014.doi
Yardley, M. M; Neely, M.; Huynh, N.; Asatryan, L.; Louie, S. G; Alkana, R. L and Davies, D. LMultiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. In Neuroreport, 25 (13): 1018-1023, 2014.doi
Neely, M.; Kaplan, E. L; Blumer, J. L; Faix, D. J and Broderick, M. PSerum Penicillin G Concentrations Are Below Inhibitory Concentrations by Two Weeks After Benzathine Penicillin G Injection in the Majority of Young Adults: A Population Pharmacokinetic Modeling Approach. In Antimicrobial Agents and Chemotherapy: AAC.02744-14, 2014.doi
Lodise, T. P; Drusano, G. L; Zasowski, E.; Dihmess, A.; Lazariu, V.; Cosler, L. and McNutt, L-A.Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?. In Clinical Infectious Diseases, 59 (5): 666-675, 2014.doi
Goutelle, S.; Bourguignon, L.; Maire, P.; Jelliffe, R. W and Neely, M. NThe Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy. In Current pharmaceutical design, 2014.
Sheth, A N; Evans-Strickfaden, T; Haaland, R; Martin, A; Gatcliffe, C; Adesoye, A; Omondi, M W; Lupo, L D; Danavall, D; Easley, K; Chen, C Y; Pau, C P; Hart, C and Ofotokun, IHIV-1 Genital Shedding is Suppressed in the Setting of High Genital Antiretroviral Drug Concentrations Throughout the Menstrual Cycle. In Journal of Infectious Diseases, 210 (5): 736-744, 2014.doi
Le, J.; Ngu, B.; Bradley, J. S; Murray, W.; Nguyen, A.; Nguyen, L.; Romanowski, G. L; Vo, T. and Capparelli, E. VVancomycin monitoring in children using bayesian estimation.doiwww
Bartroff, J.; Lai, T. L. and Narasimhan, B.A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies. In Statistics in Medicine, 33 (16): 2718-2735, 2014.doi
Felton, T W; Roberts, J A; Lodise, T P; Van Guilder, M.; Boselli, E; Neely, M N and Hope, W WIndividualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. In Antimicrobial Agents and Chemotherapy, 58 (7): 4094-4102, 2014.doi
Pai, M. P; Neely, M.; Rodvold, K. A and Lodise, T. PInnovative approaches to optimizing the delivery of vancomycin in individual patients. In Advanced Drug Delivery Reviews: 1-8, 2014.doi
Roberts, J. A; Abdul-Aziz, M. H; Lipman, J.; Mouton, J. W; Vinks, A. A; Felton, T. W; Hope, W. W; Farkas, A.; Neely, M. N; Schentag, J. J; Drusano, G.; Frey, O. R; Theuretzbacher, U.; Kuti, J. L; Pharmacology, on b. of T. I. S. of A-I.; Pharmacokinetics, t.; Microbiology, P. S. G. of t. E. S. of C. and Diseases, I.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. In The Lancet Infectious Diseases, 14 (6): 498-509, 2014.doi
Jelliffe, R. W; Milman, M.; Schumitzky, A.; Bayard, D. and Van Guilder, M.A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage.doiwww
Jelliffe, R. WThe role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to regular sinus rhythm. In Clinical Pharmacokinetics, 53 (5): 397-407, 2014.doi
Woillard, Jb; Lebreton, V; Neely, M; Turlure, P; Girault, S; Debord, J; Marquet, P and Saint-Marcoux, FPharmacokinetic tools for the dose adjustment of cyclosporine in Hematopoietic Stem Cell transplant patients. In British Journal of Clinical Pharmacology: n/a-n/a, 2014.doi
Lunde, I.; Bremer, S.; Midtvedt, K.; Mohebi, B.; Dahl, M.; Bergan, S.; AAsberg, A. and Christensen, H.The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. In European Journal of Clinical Pharmacology, 70 (6): 685-693, 2014.doi
Kinney, M E; Lamberski, N; Wack, R; Foster, R; Neely, M; Tell, L and Gehring, RPopulation pharmacokinetics of a single intramuscular administration of tulathromycin in adult desert tortoises (Gopherus agassizii). In Journal of veterinary pharmacology and therapeutics, 2014.doi
Owusu Obeng, A.; Egelund, E. F; Alsultan, A.; Peloquin, C. A and Johnson, J. ACYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?. In Pharmacotherapy, 34 (7): 703-718, 2014.doi
AAsberg, A; Bjerre, A and Neely, MNew algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. In Pediatric transplantation, 18 (1): 103-111, 2014.doi
Neely, M. N; Youn, G.; Jones, B.; Jelliffe, R. W; Drusano, G. L; Rodvold, K. A and Lodise, T. PAre vancomycin trough concentrations adequate for optimal dosing?. In Antimicrobial Agents and Chemotherapy, 58 (1): 309-316, 2014.doi
Atrio, J.; Stanczyk, F. Z; Neely, M.; Cherala, G.; Kovacs, A. and Mishell, D. REffect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women. In Journal of Acquired Immune Deficiency Syndromes, 65 (1): 72-77, 2014.doi
Drusano, G. L; Neely, M.; Van Guilder, M.; Schumitzky, A.; Brown, D.; Fikes, S.; Peloquin, C. and Louie, A.Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. In PloS one, 9 (7): e101311-e101311, 2014.doi
Tatarinova, T.; Kryshchenko, A.; Triska, M.; Hassan, M.; Murphy, D.; Neely, M. and Schumitzky, A.NPEST: a nonparametric method and a database for transcription start site prediction. In Quantitative Biology, 2014.doi
Allegaert, K. and van den Anker, J. NClinical pharmacology in neonates: small size, huge variability. In Neonatology, 105 (4): 344-349, 2014.doi
2013
Felton, T W; Goodwin, J; O'Connor, L; Sharp, A; Gregson, L; Livermore, J; Howard, S J; Neely, M N and Hope, W WImpact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. In Antimicrobial Agents and Chemotherapy, 57 (12): 5811-5819, 2013.doi
Loo, A. S; Neely, M.; Anderson, E. J; Ghossein, C.; McLaughlin, M. M and Scheetz, M. HPharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis. In Antimicrobial Agents and Chemotherapy, 57 (12): 5854-5859, 2013.doi
AAsberg, A.; Midtvedt, K.; van Guilder, M.; Storset, E.; Bremer, S.; Bergan, S.; Jelliffe, R.; Hartmann, A. and Neely, M. NInclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. In Transplant International, 26 (12): 1198-1207, 2013.doi
Narita, A.; Muramatsu, H.; Sakaguchi, H.; Doisaki, S.; Tanaka, M.; Hama, A.; Shimada, A.; Takahashi, Y.; Yoshida, N.; Matsumoto, K.; Kato, K.; Kudo, K.; Furukawa-Hibi, Y.; Yamada, K. and Kojima, S.Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children. In Journal of Pediatric Hematology/Oncology, 35 (5): e219-e223, 2013.doi
O'Connor, L.; Livermore, J.; Sharp, A. D; Goodwin, J.; Gregson, L.; Howard, S. J; Felton, T. W; Schwartz, J. A; Neely, M. N; Harrison, T. S; Perfect, J. R. and Hope, W. WPharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. In Journal of Infectious Diseases, 208 (2): 351-361, 2013.doi
Hope, W. W; Vanguilder, M.; Donnelly, J. P.; Blijlevens, N. M A; Bruggemann, R. J M; Jelliffe, R. W and Neely, M. NSoftware for dosage individualization of voriconazole for immunocompromised patients. In Antimicrobial Agents and Chemotherapy, 57 (4): 1888-1894, 2013.doi
Tatarinova, T.; Neely, M.; Bartroff, J.; Van Guilder, M.; Yamada, W.; Bayard, D.; Jelliffe, R.; Leary, R.; Chubatiuk, A. and Schumitzky, A.Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. In Journal of Pharmacokinetics and Pharmacodynamics, 40 (2): 189-199, 2013.doi
McCune, J. S; Baker, K S.; Blough, D. K; Gamis, A.; Bemer, M. J; Kelton-Rehkopf, M. C; Winter, L. and Barrett, J. SVariation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. In Journal of Clinical Pharmacology, 53 (3): 264-275, 2013.doi
Neely, M.; Rutstein, R.; Del Bianco, G.; Heresi, G.; Barton, T.; Wiznia, A.; Wiegand, R.; Wheeling, T.; Bohannon, B. and Dominguez, K.Use of Nucleoside Reverse Transcriptase Inhibitor Only Regimens in HIV-infected Children and Adolescents. In Pediatric Infectious Disease Journal: 1, 2013.doi
Sedghizadeh, P. P; Jones, A. C; LaVallee, C.; Jelliffe, R. W; Le, A. D; Lee, P.; Kiss, A. and Neely, M.Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. In Oral surgery, oral medicine, oral pathology and oral radiology, 115 (2): 224-232, 2013.doi
Choi, S-H.; Lee, S-Y.; Hwang, J-Y.; Lee, S. H.; Yoo, K. H.; Sung, Ki W.; Koo, H. H. and Kim, Y-J.Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. In Pediatric Blood & Cancer, 60 (1): 82-87, 2013.doi
Matar, K. M; Al-lanqawi, Y.; Abdul-Malek, K. and Jelliffe, R.Amikacin population pharmacokinetics in critically ill Kuwaiti patients. In BioMed research international, 2013: 202818, 2013.doi
Zhao, W.; Piana, C.; Danhof, M.; Burger, D.; Della Pasqua, O. and Jacqz-Aigrain, E.Population pharmacokinetics of abacavir in infants, toddlers and children. In British Journal of Clinical Pharmacology: -, 2012.doi
Schaudinn, C.; Gorur, A.; Webster, P.; Jones, A. C; Neely, M.; Jelliffe, R. W; Le, A. D and Sedghizadeh, P. PQuantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis. In Oral surgery, oral medicine, oral pathology and oral radiology, 114 (4): 480-486, 2012.doi
Krekels, E H J; Neely, M; Panoilia, E; Tibboel, D; Capparelli, E; Danhof, M; Mirochnick, M and Knibbe, C A JFrom Pediatric Covariate Model to Semiphysiological Function for Maturation: Part ItextendashExtrapolation of a Covariate Model From Morphine to Zidovudine. In CPT: Pharmacometrics & Systems Pharmacology, 1 (10): e9-, 2012.doi
Montoya, J. G JG; Neely, M. N MN; Gupta, S. S; Lunn, M. R MR; Loomis, K. S KS; Pritchett, J. C JC; Polsky, B. B and Medveczky, P. G PGAntiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction. In Journal of Clinical Virology, 55 (1): 40-45, 2012.doi
Neely, M. N; van Guilder, M. G; Yamada, W. M; Schumitzky, A. and Jelliffe, R. WAccurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. In Therapeutic drug monitoring, 34 (4): 467-476, 2012.doi
Felton, T W; Hope, W W; Lomaestro, B M; Butterfield, J M; Kwa, A L; Drusano, G.L. and Lodise, T PPopulation pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. In Antimicrobial Agents and Chemotherapy, 56 (8): 4087-4094, 2012.doi
Pascual, A.; Csajka, C.; Buclin, T.; Bolay, S.; Bille, J.; Calandra, T. and Marchetti, O.Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. In Clinical Infectious Diseases, 55 (3): 381-390, 2012.doi
Jelliffe, R. WSome comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.doiwww
Dolton, M. J; Ray, J. E; Chen, S. C-A.; Ng, K.; Pont, L. G and McLachlan, A. JVoriconazole Pharmacokinetics and Therapeutic Drug Monitoring: A Multi-Center Study. In Antimicrobial Agents and Chemotherapy, 56 (9): 4793-4799, 2012.doi
Arab-Alameddine, M.; Fayet-Mello, A.; Lubomirov, R.; Neely, M.; di Iulio, J.; Owen, A.; Boffito, M.; Cavassini, M.; G"unthard, H. F; Rentsch, K.; Buclin, T.; Aouri, M.; Telenti, A.; Decosterd, L. A.; Rotger, M.; Csajka, C. and Group, S. H. C. S.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. In Antimicrobial Agents and Chemotherapy, 56 (6): 2959-2966, 2012.doi
Rakhmanina, N. Y; Neely, M. N and Capparelli, E. VHigh dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count.doiwww
Homans, J.; Christensen, S.; Stiller, T.; Wang, C-H.; Mack, W.; Anastos, K.; Minkoff, H.; Young, M.; Greenblatt, R.; Cohen, M.; Strickler, H.; Karim, R.; Spencer, L. Y.; Operskalski, E.; Frederick, T. and Kovacs, A.Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. In Journal of Acquired Immune Deficiency Syndromes, 60 (1): 99-110, 2012.doi
Kelly, L E; Rieder, M; van den Anker, J; Malkin, B; Ross, C; Neely, M N; Carleton, B; Hayden, M R; Madadi, P and Koren, GMore Codeine Fatalities After Tonsillectomy in North American Children. In Pediatrics, 129 (5): e1343-e1347, 2012.doi
Zhao, W. W; Cella, M. M; Della Pasqua, O. O; Burger, D. D and Jacqz-Aigrain, E. EPopulation pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. In British Journal of Clinical Pharmacology, 73 (4): 641-650, 2012.doi
Charhon, N.; Neely, M. N; Bourguignon, L.; Maire, P.; Jelliffe, R. W and Goutelle, S.Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients. In Antimicrobial Agents and Chemotherapy, 56 (4): 1862-1869, 2012.doi
Doby, E. H; Benjamin, D. K; Blaschke, A. J; Ward, R. M; Pavia, A. T; Martin, P. L; Driscoll, T. A; Cohen-Wolkowiez, M. and Moran, C.Therapeutic Monitoring of Voriconazole in Children Less Than 3 Years of Age: A Case Report and Summary of Voriconazole Concentrations for 10 Children. In Pediatric Infectious Disease Journal, 2012.doi
Siberry, G. K; Frederick, T.; Emmanuel, P.; Paul, M. E; Bohannon, B.; Wheeling, T.; Barton, T.; Rathore, M. H and Dominguez, K. LMethicillin-Resistant Staphylococcus aureus Infections in Human Immunodeficiency Virus-Infected Children and Adolescents. In AIDS research and treatment, 2012: 627974, 2012.doi
2011
Neely, M. and Louie, S.Obesity and its impact on drug therapy: are we ready for this change?. In Clinical Pharmacokinetics, 50 (12): 825-826, 2011.doi
Schein, R; Homans, J; Larsen, R A and Neely, MPosaconazole for Chronic Refractory Coccidioidal Meningitis. In Clinical Infectious Diseases, 53 (12): 1252-1254, 2011.doi
Troke, P.F.; Hockey, H P and Hope, W WObservational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. In Antimicrobial Agents and Chemotherapy, 55 (10): 4782-4788, 2011.doi
Bondareva, I.B.; Jelliffe, R W; Andreeva, O V and Bondareva, K IPredictability of individualized dosage regimens of carbamazepine and valproate. In Journal of clinical pharmacy and therapeutics, 36 (5): 625-636, 2011.doi
Jelliffe, R.; Neely, M.; Schumitzky, A.; Bayard, D.; Van Guilder, M.; Botnen, A.; Bustad, A.; Laing, D.; Yamada, W.; Bartroff, J. and Tatarinova, T.Nonparametric population modeling and Bayesian analysis. In Pharmacol Res., 64 (4): 426, 2011.doi
Goutelle, S.; Bourguignon, L.; Jelliffe, R. W; Conte, J. E Jr and Maire, P.Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin. In J Theor.Biol., 282 (1): 80-92, 2011.doi
Rakhmanina, N. Y; Neely, M. N; van Schaik, R. H N; Gordish-Dressman, H. A; Williams, K. D; Soldin, S. J and van den Anker, J. NCYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.doiwww
Bartroff, J. and Lai, T. L.Incorporating individual and collective ethics into phase I cancer trial designs. In Biometrics, 67 (2): 596-603, 2011.doi
Garvie, P. A; Flynn, P. M; Belzer, M.; Britto, P.; Hu, C.; Graham, B.; Neely, M.; McSherry, G. D; Spector, S. A; Gaur, A. H and Team, P. A. C. T. G. (. P.Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. In The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 48 (6): 637-640, 2011.doi
Neely, M. N and Rakhmanina, N. YPharmacokinetic optimization of antiretroviral therapy in children and adolescents. In Clinical Pharmacokinetics, 50 (3): 143-189, 2011.doi
Spriet, I; Cosaert, K; Renard, M; Uyttebroeck, A; Meyts, I; Proesmans, M; Meyfroidt, G; de Hoon, J; Verbesselt, R and Willems, LVoriconazole plasma levels in children are highly variable. In Eur J Clin Microbiol Infect Dis, 30 (2): 283-287, 2011.doi
Hassan, A.; Burhenne, J.; Riedel, K-D.; Weiss, J.; Mikus, G.; Haefeli, W. E and Czock, D.Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring.doiwww
Darbari, D. S; Neely, M.; van den Anker, J. and Rana, S.Increased Clearance of Morphine in Sickle Cell Disease: Implications for Pain Management. In The Journal of Pain, 2011.doi
McIlleron, H.; Ren, Y.; Nuttall, J.; Fairlie, L.; Rabie, H.; Cotton, M.; Eley, B.; Meyers, T.; Smith, P. J; Merry, C. and Maartens, G.Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. In Antiviral Therapy, 16 (3): 417-421, 2011.doi
Else, L. J; Taylor, S.; Back, D. J and Khoo, S. HPharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. In Antiviral Therapy, 16 (8): 1149-1167, 2011.doi
Launay, O.; Tod, M.; Tsch"ope, I.; Si-Mohamed, A.; Belarbi, L.; Charpentier, C.; Goujard, C.; Taburet, A-M.; Lortholary, O.; Leroy, V.; Belec, L. and Group, t. A. E. G. S.Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. In Antiviral Therapy, 16 (6): 843-852, 2011.doi
Watt, K.; Benjamin Jr, D. K. and Cohen-Wolkowiez, M.Pharmacokinetics of antifungal agents in children. In Early Human Development, 87: S61-S65, 2011.doi
Darbari, D S; Neely, M; van den Anker, J and Rana, SIncreased clearance of morphine in sickle cell disease: implications for pain management. In The Journal of Pain, 2011.
2010
Henning, T. R.; Kissinger, P.; Lacour, N.; Meyaski-Schluter, M.; Clark, R. and Amedee, A. M.Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. In Journal of Infectious Diseases, 202 (10): 1543-1552, 2010.doi
Neely, M.; Decosterd, L.; Fayet, A.; Lee, J. S. F.; Margol, A.; Kanani, M.; di Iulio, J.; von Schoen-Angerer, T.; Jelliffe, R. and Calmy, A.Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. In Antimicrobial Agents and Chemotherapy, 54 (11): 4619-4625, 2010.doi
Walsh, T.J.; Driscoll, T; Milligan, P A; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H; Arrieta, A C; Klein, N J and Lutsar, I.Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. In Antimicrobial Agents and Chemotherapy, 54 (10): 4116-4123, 2010.doi
Gaur, A. H; Belzer, M.; Britto, P.; Garvie, P. A; Hu, C.; Graham, B.; Neely, M.; McSherry, G.; Spector, S. A; Flynn, P. M and Team, P. A. C. T. G. P.Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. In AIDS Research and Human Retroviruses, 26 (9): 947-953, 2010.doi
Walsh, T. J; Goutelle, S.; Jelliffe, R. W; Golden, J. A; Little, E. A; DeVoe, C.; Mickiene, D.; Hayes, M. and Conte, J. E JrIntrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. In Antimicrobial Agents and Chemotherapy, 54 (8): 3451-3459, 2010.doi
Michael, C.; Bierbach, U.; Frenzel, K.; Lange, T.; Basara, N.; Niederwieser, D.; Mauz-Korholz, C. and Preiss, R.Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. In Antimicrobial Agents and Chemotherapy, 54 (8): 3225-3232, 2010.doi
Neely, M. and Jelliffe, R.Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. In Journal of Clinical Pharmacology, 50 (7): 842-847, 2010.doi
Rakhmanina, N. Y; van den Anker, J. N; Soldin, S. J; van Schaik, R. H; Mordwinkin, N. and Neely, M. NCan therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?. In Therapeutic drug monitoring, 32 (3): 273-281, 2010.doi
Neely, M. N and Rakhmanina, N. YComment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. In Journal of Antimicrobial Chemotherapy, 65 (4): 808-9; author reply 809-10, 2010.doi
Neely, M.; Rushing, T.; Kovacs, A.; Jelliffe, R. and Hoffman, J.Voriconazole Pharmacokinetics and Pharmacodynamics in Children. In Clinical Infectious Diseases, 50 (1): 27-36, 2010.doi
Walsh, T. J; Driscoll, T.; Milligan, P. A; Wood, N. D.; Schlamm, H.; Groll, A. H.; Jafri, H.; Arrieta, A. C.; Klein, N. J. and Lutsar, I.Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. In Antimicrobial Agents and Chemotherapy, 54 (10): 4116-4123, 2010.doi
Michael, C.; Bierbach, U.; Frenzel, K.; Lange, T.; Basara, N.; Niederwieser, D.; Mauz-Korholz, C. and Preiss, R.Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients. In Antimicrobial Agents and Chemotherapy, 54 (8): 3225-3232, 2010.doi
Elsherbiny, D.; Ren, Y.; McIlleron, H.; Maartens, G. and Simonsson, U. S HPopulation pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. In European Journal of Clinical Pharmacology, 2010.doi
Bartroff, J. and Lai, T. LApproximate dynamic programming and its applications to the design of phase I cancer trials. In Statistical Science, 25 (2): 245-257, 2010.
Miyakis, S.; van Hal, S. J; Solvag, C. J. S; Ray, J. and Marriott, D.Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.doiwww
2009
Goutelle, S.; Bourguignon, L.; Bertrand-Passeron, N.; Jelliffe, R. W and Maire, P.Visual estimation of patients' body weight in hospital: the more observers, the better?. In Pharmacy world & science : PWS, 31 (4): 422-425, 2009.doi
Goutelle, S.; Bourguignon, L.; Maire, P. H; Van Guilder, M.; Conte, J. E and Jelliffe, R. WPopulation modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. In Antimicrobial Agents and Chemotherapy, 53 (7): 2974-2981, 2009.doi
Rakhmanina, N.; van den Anker, J.; Baghdassarian, A.; Soldin, S.; Williams, K. and Neely, M. NPopulation pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. In Antimicrobial Agents and Chemotherapy, 53 (6): 2532-2538, 2009.doi
Neely, M. and Kovacs, A.Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. In Therapeutics and clinical risk management, 5 (3): 595-615, 2009.
Sleasman, J W; Robbins, B L; Cross, S J; Lindsey, J C; Kraimer, J M; Heckman, B E; Sprenger, H L; Tustin, N B; Rose, C H; Poston, P A; Neal, E F; Pakes, G E; Nikanjam, M and Capparelli, E VAbacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. In Clinical Pharmacology and Therapeutics, 85 (4): 394-401, 2009.doi
Troukhan, M.; Tatarinova, T.; Bouck, J.; Flavell, R. B and Alexandrov, N. NGenome-wide discovery of cis-elements in promoter sequences using gene expression. In Omics : a journal of integrative biology, 13 (2): 139-151, 2009.doi
Jelliffe, R.; Schumitzky, A.; Bayard, D.; Leary, R.; Botnen, A.; Guilder, M. V.; Bustad, A. and Neely, MHuman Genetic Variation, Population Pharmacokinetic-Dynamic Models, Bayesian Feedback Control, and Maximally Precise Individualized Drug Dosage Regimens. In Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacog, 7 (4): 249-262, 2009.
2008
Jelliffe, R.Estimation of creatinine clearance.doiwww
Neely, M. and Jelliffe, R.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.doiwww
Tatarinova, T.; Bouck, J. and Schumitzky, A.Kullback-Leibler Markov chain Monte Carlo--a new algorithm for finite mixture analysis and its application to gene expression data. In Journal of bioinformatics and computational biology, 6 (4): 727-746, 2008.
Kwa, A.; Sprung, J.; Guilder, M. V. and Jelliffe, R. WA population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine.www
Macdonald, I.; Staatz, C. E; Jelliffe, R. W and Thomson, A. HEvaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. In Therapeutic drug monitoring, 30 (1): 67-74, 2008.doi
Kiser, J J; Carten, M L; Aquilante, C L; Anderson, P.L.; Wolfe, P; King, T M; Delahunty, T; Bushman, L R and Fletcher, C VThe effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. In Clinical Pharmacology and Therapeutics, 83 (2): 265-272, 2008.doi
2007
Greenhalgh, D. G; Saffle, J. R; Holmes IV, J. H; Gamelli, R. L; Palmieri, T. L; Horton, J. W; Tompkins, R. G; Traber, D. L; Mozingo, D. W; Deitch, E. A; Goodwin, C. W; Herndon, D. N; Gallagher, J. J; Sanford, A. P; Jeng, J. C; Ahrenholz, D. H; Neely, A. N; O'Mara, M. S; Wolf, S. E; Purdue, G. F; Garner, W. L; Yowler, C. J and Latenser, B. AAmerican Burn Association Consensus Conference to Define Sepsis and Infection in Burns. In Journal of Burn Care & Research, 28 (6): 776-790, 2007.doi
Neely, M. N; Benning, L.; Xu, J.; Strickler, H. D; Greenblatt, R. M; Minkoff, H.; Young, M.; Bremer, J.; Levine, A. M and Kovacs, A.Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. In Journal of Acquired Immune Deficiency Syndromes, 44 (1): 38-42, 2007.doi
2006
Shoemaker, W. C; Wo, C. C J; Lu, K.; Chien, L-C.; Rhee, P.; Bayard, D.; Demetriades, D. and Jelliffe, R. WNoninvasive hemodynamic monitoring for combat casualties. In Military medicine, 171 (9): 813-820, 2006.
Shoemaker, W. C; Bayard, D. S.; Wo, C. C J; Botnen, A.; Chan, L. S; Chien, L-C.; Lu, K.; Demetriades, D.; Belzberg, H. and Jelliffe, R. WStochastic model for outcome prediction in acute illness. In Computers in Biology and Medicine, 36 (6): 585-600, 2006.doi
Bondareva, I.B.; Jelliffe, R W; Gusev, E I; Guekht, A B; Melikyan, E G and Belousov, Y BPopulation pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. In Journal of clinical pharmacy and therapeutics, 31 (3): 211-221, 2006.doi
Benjamin, D K; Driscoll, T; Seibel, N L; Gonzalez, C E; Roden, M M; Kilaru, R; Clark, K; Dowell, J A; Schranz, J and Walsh, T.J.Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections. In Antimicrobial Agents and Chemotherapy, 50 (2): 632-638, 2006.doi
Shoemaker, W. C; Wo, C. C J; Lu, K.; Chien, L-C.; Bayard, D. S.; Belzberg, H.; Demetriades, D. and Jelliffe, R. WOutcome prediction by a mathematical model based on noninvasive hemodynamic monitoring. In J Trauma, 60 (1): 82-90, 2006.doi
Bustad, A.; Terziivanov, D.; Leary, R.; Port, R.; Schumitzky, A. and Jelliffe, R.Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. In Clinical Pharmacokinetics, 45 (4): 365-383, 2006.
2005
Adamson, P.; Walsh, T. J; Seibel, N. L; Flynn, P. M; Neely, M. N; Schwartz, C.; Shad, A.; Kaplan, S. L; Roden, M. M; Stone, J. A; Miller, A.; Bradshaw, S. K; Li, S. X; Sable, C. A and Kartsonis, N. APharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. In Antimicrobial Agents and Chemotherapy, 49 (11): 4536-4545, 2005.doi
Shoemaker, W. C; Bayard, D. S.; Wo, C. C J; Chan, L. S; Chien, L-C.; Lu, K. and Jelliffe, R. WOutcome prediction in chest injury by a mathematical search and display program. In Chest, 128 (4): 2739-2748, 2005.doi
Shoemaker, W. C; Bayard, D. S.; Botnen, A.; Wo, C. C J; Gandhi, A.; Chien, L-C.; Lu, K.; Martin, M. J; Chan, L. S; Demetriades, D.; Ahmadpour, N. and Jelliffe, R. WMathematical program for outcome prediction and therapeutic support for trauma beginning within 1 hr of admission: a preliminary report. In Critical care medicine, 33 (7): 1499-1506, 2005.
Shoemaker, W. C; Bayard, D. S.; Wo, C. C J; Botnen, A.; Ahmedpour, N.; Gandhi, A.; Demetriades, D. and Jelliffe, R. WA stochastic control program to predict outcome and to support therapeutic decisions: a preliminary report. In Journal of clinical monitoring and computing, 19 (3): 223-230, 2005.doi
2004
Gan, S H; Ismail, R; Wan Adnan, W A; Zulmi, W and Jelliffe, R WPopulation pharmacokinetic modelling of tramadol with application of the NPEM algorithms. In Journal of clinical pharmacy and therapeutics, 29 (5): 455-463, 2004.doi
Neely, M. and Kovacs, A.Management of antiretroviral therapy in neonates, children, and adolescents. In Current HIV/AIDS reports, 1 (2): 97-104, 2004.
Bondareva, I.B.; Jelliffe, R W; Sokolov, A.V. and Tischenkova, I.F.Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. In Journal of clinical pharmacy and therapeutics, 29 (2): 105-120, 2004.
Port, R. E; Kiepe, D.; Van Guilder, M.; Jelliffe, R. W and Mehls, O.Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage. In Clinical Pharmacokinetics, 43 (1): 57-70, 2004.doi
Neely, M. and Kovacs, A.Management of Antiretroviral Therapy in Neonates, Children, and Adolescents. In Current infectious disease reports, 5 (6): 521-530, 2003.
Martin, P; Bleyzac, N.; Souillet, G; Galambrun, C; Bertrand, Y; Maire, P.H.; Jelliffe, R W and Aulagner, G.Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. In Bone Marrow Transplantation, 32 (9): 881-887, 2003.
Neely, M.; Kalyesubula, I.; Bagenda, D.; Myers, C. and Olness, K.Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. In African Health Sciences, 3 (2): 61-67, 2003.
Rougier, F; Corvaisier, S.; Ducher, M.; Claude, D; Jelliffe, R W and Maire, P.[PK/PD modeling of aminoglycoside nephrotoxicity]. In Pathol.Biol.(Paris), 51 (4): 234-236, 2003.
Rougier, F.; Claude, D.; Maurin, M.; Sedoglavic, A.; Ducher, M.; Corvaisier, S.; Jelliffe, R. and Maire, P.Aminoglycoside nephrotoxicity: modeling, simulation, and control. In Antimicrobial Agents and Chemotherapy, 47 (3): 1010-1016, 2003.
Vinks, A. A; Den Hollander, J. G; Overbeek, S. E; Jelliffe, R. W and Mouton, J. WPopulation pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. In Antimicrobial Agents and Chemotherapy, 47 (2): 541-547, 2003.
Rougier, F.; Ducher, M.; Maurin, M.; Corvaisier, S.; Claude, D.; Jelliffe, R. and Maire, P.Aminoglycoside dosages and nephrotoxicity: quantitative relationships. In Clinical Pharmacokinetics, 42 (5): 493-500, 2003.doi
A, B.; C, P. and Jelliffe, R.Gentamicin Ototoxicity: Characteristics of Patient Response Analyzed with Saturable Michaelis-Menten Models. In Presented at the 4th International Meeting on Mathematical Modeling, Technical University of Vienna, Vienna, Austria, 2003.
2002
Bayard, D.Proof of quasi-adaptivity for the m-measurement feedback class of stochastic control policies. In Automatic Control, IEEE Transactions, 32 (5): 447-451, 2002.
Aminimanizani, A.; Beringer, P.M.; Kang, J.; Tsang, L.; Jelliffe, R W and Shapiro, B.J.Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. In Journal of Antimicrobial Chemotherapy, 50 (4): 553-559, 2002.
Nelson, P. W and Perelson, A. SMathematical analysis of delay differential equation models of HIV-1 infection. In Mathematical Biosciences, 179 (1): 73-94, 2002.
2001
Montgomery, M J; Beringer, P.M.; Aminimanizani, A.; Louie, S G; Shapiro, B.J.; Jelliffe, R. and Gill, M.A.Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. In Antimicrobial Agents and Chemotherapy, 45 (12): 3468-3473, 2001.doi
Bondareva, I.B.; Sokolov, A.V.; Tischenkova, I.F. and Jelliffe, R WPopulation pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage. In Journal of clinical pharmacy and therapeutics, 26 (3): 213-223, 2001.
Milman, M.; Jiang, F. and Jelliffe, R.Creating discrete joint densities from continuous ones: the moment matching-maximum entropy approach. In Computers in Biology and Medicine, 31 (3): 197-214, 2001.
Labaune, J.M.; Bleyzac, N.; Maire, P.; Jelliffe, R W; Boutroy, M.J.; Aulagner, G. and Putet, G.Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. In Biol.Neonate, 80 (2): 142-147, 2001.
Bleyzac, N.; Souillet, G; Magron, P.; Janoly, A.; Martin, P; Bertrand, Y; Galambrun, C; Dai, Q.; Maire, P.; Jelliffe, R W and Aulagner, G.Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. In Bone Marrow Transplantation, 28 (8): 743-751, 2001.
Aminimanizani, A.; Beringer, P and Jelliffe, R.Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. In Clinical Pharmacokinetics, 40 (3): 169-187, 2001.doi
Ducher, M.; Maire, P.; Cerutti, C.; Bourhis, Y; Foltz, F; Sorensen, P; Jelliffe, R. and Fauvel, J.P.Renal elimination of amikacin and the aging process. In Clinical Pharmacokinetics, 40 (12): 947-953, 2001.doi
Jelliffe, R W and Maire, P.Goal-oriented, model-based drug regimens. In Comput.Biol.Med., 31 (3): 145-146, 2001.
Breilh, D.; Saux, M.C.; Maire, P.; Vergnaud, J.M. and Jelliffe, R WMixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. In Comput.Biol.Med., 31 (3): 147-155, 2001.
Bleyzac, N.; Varnier, V.; Labaune, J.M.; Corvaisier, S.; Maire, P.; Jelliffe, R W; Putet, G. and Aulagner, G.Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. In Eur.J.Clin.Pharmacol., 57 (6-7): 499-504, 2001.
Zhu, M; Burman, W J; Jaresko, G S; Berning, S E; Jelliffe, R W and Peloquin, C APopulation pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. In Pharmacotherapy, 21 (9): 1037-1045, 2001.
Leary, R.H.; Jelliffe, R.; Schumitzky, A. and Van Guilder, M.An adaptive grid non-parametric approach to population pharmacokinetic/dynamic (PK/PD) population models. In Proceedings, 14th IEEE symposium on Computer Based Medical Systems, 1 (1): 389-394, 2001.
Macchi-Andanson, M.; Charpiat, B.; Jelliffe, R W; Ducerf, C.; Fourcade, N. and Baulieux, J.Failure of traditional trough levels to predict tacrolimus concentrations.www
2000
Jelliffe, R.; Bayard, D.; Milman, M.; Van Guilder, M. and Schumitzky, A.Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens. In Therapeutic drug monitoring, 22 (3): 346-353, 2000.
Bleyzac, N.; Allard-Latour, B; Laffont, A.; Mouret, J; Jelliffe, R. and Maire, P.Diurnal changes in the pharmacokinetic behavior of amikacin.www
Jelliffe, R.Goal-oriented, model-based drug regimens: setting individualized goals for each patient.www
Jelliffe, R.; Schumitzky, A. and Van Guilder, M.Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods.www
Beringer, P.M.; Vinks, A.A.; Jelliffe, R W and Shapiro, B.J.Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. In Antimicrobial Agents and Chemotherapy, 44 (4): 809-813, 2000.
Leary, R.H.Global Optimization on Funneling Landscapes. In Journal of Global Optimization, 18: 367-383, 2000.
1999
Peloquin, C A; Bulpitt, A E; Jaresko, G S; Jelliffe, R W; Childs, J.M. and Nix, D EPharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. In Antimicrobial Agents and Chemotherapy, 43 (3): 568-572, 1999.
Leary, R.H. and Doye, J.P.K.Tetrahedral global minimum for the 98-atom Lennard-Jones cluster. In Physical Review E, 60: R6320-R6322, 1999.
1998
Corvaisier, S.; Maire, P.H.; Bouvier d'Yvoire, M.Y.; Barbaut, X.; Bleyzac, N. and Jelliffe, R WComparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. In Antimicrobial Agents and Chemotherapy, 42 (7): 1731-1737, 1998.
Charpiat, B.; Falconi, I.; Breant, V.; Jelliffe, R W; Sab, J.M.; Ducerf, C.; Fourcade, N.; Thomasson, A. and Baulieux, J.A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting.www
Shafran, S.D.; Singer, J.; Zarowny, D.P.; Deschenes, J.; Phillips, P.; Turgeon, F.; Aoki, F.Y.; Toma, E.; Miller, M.; Duperval, R.; Lemieux, C. and Schlech, W.F.Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. In Journal of Infectious Diseases, 177 (1): 252-255, 1998.
Jelliffe, R W; Schumitzky, A.; Bayard, D.; Milman, M.; Van Guilder, M.; Wang, X.; Jiang, F.; Barbaut, X. and Maire, P.Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals. In Clinical Pharmacokinetics, 34 (1): 57-77, 1998.
Beringer, P.M.; Vinks, A.A. and Jelliffe, R WPharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. In Journal of Antimicrobial Chemotherapy, 41 (1): 142-144, 1998.
Peloquin, C A; Bulpitt, A E; Jaresko, G S; Jelliffe, R W; James, G.T. and Nix, D EPharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. In Pharmacotherapy, 18 (6): 1205-1211, 1998.
1997
Peloquin, C A; Jaresko, G S; Yong, C L; Keung, A C; Bulpitt, A E and Jelliffe, R WPopulation pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. In Antimicrobial Agents and Chemotherapy, 41 (12): 2670-2679, 1997.
Jelliffe, R W; Gomis, P.; Tahani, B.; Ruskin, J. and Sattler, F.R.A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods.www
1996
Vincent, S.; Maire, P.H.; Bataillard, T.; Denjean, E.; Ducrozet, P.; Laffont, A.; Visent, C. and Jelliffe, R W[Individual variability of pharmacokinetic parameters of amikacin in the elderly: retrospective studies]. In Pathol.Biol.(Paris), 44 (7): 667-674, 1996.
Breant, V.; Charpiat, B.; Sab, J.M.; Maire, P. and Jelliffe, R WHow many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine. In European Journal of Clinical Pharmacology, 51 (3-4): 283-288, 1996.
1995
Maire, P.H.; Barbaut, X.; Thalabard, J.C.; Vergnaud, J.M.; Roux, D.; Roy, M. and Jelliffe, R WAdaptive control of therapeutic drug regimens relations between clinical situations: outcomes and simulations using nonlinear dynamic models. In Medinfo., 8 Pt 2: 1111-1115, 1995.
Jelliffe, R W; Bayard, D.; Schumitzky, A.; Milman, M. and Van Guilder, M.Pharmaco-informatics: more precise drug therapy from 'multiple model' (MM) adaptive control regimens: evaluation with simulated vancomycin therapy. In Medinfo., 8 Pt 2: 1106-1110, 1995.
1994
Dodge, W.F.; Jelliffe, R W; Zwischenberger, J.B.; Bellanger, R.A.; Hokanson, J.A. and Snodgrass, W.R.Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation.www
Jelliffe, R W; Maire, P.; Sattler, F.; Gomis, P. and Tahani, B.Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples. In International Journal of Bio-Medical Computing, 36 (1-2): 1-23, 1994.
Neef, C.; Jelliffe, R W; van Laar, T.; Loohuis, T.; Essink, A.W. and Janssen, E.N.Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. In International Journal of Bio-Medical Computing, 36 (1-2): 143-150, 1994.
Maire, P.; Barbaut, X.; Vergnaud, J.M.; el Brouzi, M.; Confesson, M.A.; Pivot, C.; Chuzeville, M.; Ivanoff, N.; Brazier, J.L. and Jelliffe, R WComputation of drug concentrations in endocardial vegetations in patients during antibiotic therapy. In International Journal of Bio-Medical Computing, 36 (1-2): 77-85, 1994.
Maire, P.; Barbaut, X.; Girard, P.; Mallet, A.; Jelliffe, R W and Berod, T.Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients. In International Journal of Bio-Medical Computing, 36 (1-2): 139-141, 1994.
Grillot, M.; Maire, P.H.; Confesson, M.A.; Cogoluenhes, V.; Pivot, C.; Druguet, M.; Courpron, P. and Jelliffe, R W[Adaptive control of therapeutics using amikacin in very old patients: retrospective analysis of efficacy and toxicity]. In Pathol.Biol.(Paris), 42 (3): 247-253, 1994.
Confesson, M.A.; Barbaut, X.; Maire, P.; Vergnaud, J.M.; el Brouzi, A. and Jelliffe, R W[Aminoglycoside determinations calculated in endocarditis vegetations. Relations with clinical practices during infectious endocarditis treatment with amikacin]. In Therapie, 49 (1): 27-34, 1994.
Bayard, D.S.; Milman, M. H. and Schumitzky, A.Design of dosage regimens: A multiple model stochastic control approach. In International Journal of Bio-Medical Computing, 36 (1-2): 103-115, 1994.
Jelliffe, R W; Bayard, D.; Schumitzky, A.; Milman, M. and Van Guilder, M.Pharmaco-informatics: more precise drug therapy from "multiple model" (MM) stochastic adaptive control regimens: evaluation with simulated vancomycin therapy. In Proceedings of the Annual Symposium of Computer Applications in Medical Care: 972, 1994.
Jelliffe, R W; Bayard, D.; Schumitzky, A.; Milman, M. and Van Guilder, M.Pharmacoinformatics: more precise drug therapy from "multiple model" (MM) stochastic adaptive control regimens: evaluation with simulated vancomycin therapy. In Proceedings of the Annual Symposium of Computer Applications in Medical Care: 972, 1994.
Charpiat, B.; Breant, V.; Pivot-Dumarest, C.; Maire, P. and Jelliffe, R.Prediction of future serum concentrations with Bayesian fitted pharmacokinetic models: results with data collected by nurses versus trained pharmacy residents.www
1993
Sittig, D.F.; Jiang, Z. and Jelliffe, R WA graphical user interface to facilitate patient-specific drug dosing. In Journal of Medical Systems, 17 (5): 327-333, 1993.
Schumitzky, A.The nonparametric maximum likelihood approach to pharmacokinetic population analysis. In Proceedings of the Western Simulation Multiconference, Simulation in Healthcare: 95-100, 1993.
Spieler, G. and Schumitzky, A.Asymptotic analysis of extended least squares estimators with application to population pharmacokinetics. In Proceedings: Biopharmaceutical Section: 177-182, 1993.
Jelliffe, R W; Schumitzky, A.; Van Guilder, M.; Liu, M.; Hu, L.; Maire, P.; Gomis, P.; Barbaut, X. and Tahani, B.Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.www
1992
Maire, P.H.; Barbaut, X. and Jelliffe, R WAntibiotic dose adjustment in renal insufficiency. In The Lancet, 340 (8833): 1478-9-author reply 1480-1, 1992.
Kisor, D.F.; Watling, S.M.; Zarowitz, B.J. and Jelliffe, R WPopulation pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm. In Clinical Pharmacokinetics, 23 (1): 62-68, 1992.
Jelliffe, R W; Schumitzky, A. and Van Guilder, M.Nonpharmacokinetic clinical factors affecting aminoglycoside therapeutic precision. In Drug Investigation, 4 (1): 20-29, 1992.doi
Schumitzky, A.Nonparametric Population Modeling. In Proceedings of the Western Simulation Multiconference, Simulation in Healthcare: 57-64, 1992.
1991
Jelliffe, R W; Iglesias, T.; Hurst, A.K.; Foo, K.A. and Rodriguez, J.Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. In Clinical Pharmacokinetics, 21 (6): 461-478, 1991.doi
Dodge, W.F.; Jelliffe, R W; Richardson, C.J.; McCleery, R.A.; Hokanson, J.A. and Snodgrass, W.R.Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. In Clinical Pharmacology and Therapeutics, 50 (1): 25-31, 1991.
Moreira, C A Jr; Moreira, A.T.; Armstrong, D.K.; Jelliffe, R W; Woodford, C.C.; Liggett, P.E. and Trousdale, M.D.In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. In Acta Ophthalmologica, 69 (1): 50-56, 1991.
Moreira, C A Jr; Armstrong, D.K.; Jelliffe, R W; Moreira, A.T.; Woodford, C.C.; Liggett, P.E. and Trousdale, M.D.Sodium hyaluronate as a carrier for intravitreal gentamicin. An experimental study. In Acta Ophthalmologica, 69 (1): 45-49, 1991.
Schumitzky, A.Nonparametric EM Algorithms for Estimating Prior Distributions. In Applied Math and Computation, 45: 141-157, 1991.
Bayard, D.S.A forward method for optimal stochastic nonlinear and adaptive control. In Automatic Control, IEEE Transactions, 36 (9): 1046-1053, 1991.
Hurst, A.K.; Yoshinaga, M.A.; Mitani, G.H.; Foo, K.A.; Jelliffe, R W and Harrison, E.C.Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. In Antimicrobial Agents and Chemotherapy, 34 (6): 1165-1171, 1990.
Jelliffe, R W and Schumitzky, A.Modeling, adaptive control, and optimal drug therapy. In Med.Prog.Technol., 16 (1-2): 95-110, 1990.
1987
Chizeck, H.J.; Jelliffe, R W and Cheung, P.W.Automatic regulation for administration of therapeutic agents. In IEEE Trans.Biomed.Eng, 34 (8): 565-566, 1987.
Jelliffe, R WClinical applications of pharmacokinetics and adaptive control. In IEEE Trans.Biomed.Eng, 34 (8): 624-632, 1987.
Jelliffe, R WDrug-receptor relationships, selection of therapeutic goals, and adaptive control of pharmacokinetic systems. In Fed.Proc., 46 (8): 2494-2501, 1987.
Hurst, A.K.; Iseri, K.T.; Gill, M.A.; Noguchi, J.K.; Gilman, T.M. and Jelliffe, R WComparison of four methods for predicting serum gentamicin concentrations in surgical patients with perforated or gangrenous appendicitis. In Clin.Pharm., 6 (3): 234-238, 1987.
Rodman, J H; Jelliffe, R W; Kolb, E.; Tuey, D.B.; de Guzman, M.F.; Wagers, P.W. and Haywood, L.J.Clinical studies with computer-assisted initial lidocaine therapy. In Archives of Internal Medicine, 144 (4): 703-709, 1984.
Jelliffe, R WDigitalis therapy: simple formulas to plan and adjust dosage regimens. In MD Comput., 1 (2): 36-41, 65, 1984.
1983
Jelliffe, R WOpen-loop-feedback control of serum drug concentrations: pharmacokinetic approaches to drug therapy. In Med.Instrum., 17 (4): 267-273, 1983.
Jelliffe, R WComputer-controlled administration of cardiovascular drugs. In Prog.Cardiovasc.Dis., 26 (1): 1-14, 1983.
1982
Rodman, J H; Hurst, A.; Gaarder, T.; Cohen, J. and Jelliffe, R WN-Acetylprocainamide kinetics and clinical response during repeated dosing. In Clinical Pharmacology and Therapeutics, 32 (3): 378-386, 1982.
1980
Haldimann, B; Healy, M; Jelliffe, R.; Goldstein, D A; Pattabhiraman, R and Massry, S GEffect of an oral dose of 25-hydroxyvitamin D3 on its blood levels in patients with the nephrotic syndrome. In The Journal of clinical endocrinology and metabolism, 50 (3): 470-474, 1980.doi
Jelliffe, R WElectrolytes and cardiac arrhythmias. In Crit Care Update., 7 (1): 5-11, 1980.
1974
Jelliffe, R W and Brooker, G.A nomogram for digoxin therapy. In American Journal of Medicine, 57 (1): 63-68, 1974.
Goicoechea, F.J. and Jelliffe, R WComputerized dosage regimens for highly toxic drugs. In American Journal of Hospital Pharmacy, 31 (1): 67-71, 1974.
1973
Jelliffe, R WEditorial: Quantitative aspects of clinical judgment. In American Journal of Medicine, 55 (3): 431-433, 1973.
Jelliffe, R WLetter: Creatinine clearance: bedside estimate. In Annals of Internal Medicine, 79 (4): 604-605, 1973.
Jelliffe, R WPlanning drug doses for patients. In Dent.Dimens., 7 (3): 6-7, 1973.
Goicoechea, F.J.; Bischel, M.D. and Jelliffe, R WKinetics of procainamide in anuric patients undergoing chronic hemodialysis. In Proc.Clin.Dial.Transplant.Forum, 3: 92-95, 1973.
1972
Jelliffe, R W; Buell, J. and Kalaba, R.Reducation of digitalis toxicity by computer-assisted glycoside dosage regimens. In Annals of Internal Medicine, 77 (6): 891-906, 1972.
Jelliffe, R W and Ivler, D.Gentamicin and kanamycin nomograms. In Annals of Internal Medicine, 77 (3): 480-481, 1972.
Jelliffe, R W; Buell, J. and Kalaba, R.Reduction of digitalis toxicity by computer-assisted glycoside dosage regimens. In Annals of Internal Medicine, 77 (6): 891-906, 1972.
Brooker, G. and Jelliffe, R WSerum cardiac glycoside assay based upon displacement of 3 H-ouabain from Na-K ATPase. In Circulation, 45 (1): 20-36, 1972.
1971
Jelliffe, R WEstimation of creatinine clearance when urine cannot be collected. In The Lancet, 1 (7706): 975-976, 1971.
Jelliffe, R WFactors to consider in planning digoxin therapy. In Journal of Chronic Diseases, 24 (7): 407-416, 1971.
Jelliffe, R W and Jelliffe, S.M.Estimation of creatinine clearance from changing serum-creatinine levels. In Lancet, 2 (7726): 710, 1971.
1970
Jelliffe, R W; Buell, J.; Kalaba, R.; Sridhar, R; Rockwell, R. and Wagner, J.G.An improved method of digitoxin therapy. In Annals of Internal Medicine, 72 (4): 453-464, 1970.
Jelliffe, RW; Buell, J.; Kalaba, R. and Sridhar, RA computer program for digitalis dosage regimens. In Mathematical Biosciences, 9: 179-193, 1970.
Jelliffe, R WAn improved method for replacing one digitalis glycoside with another. In Med.Times, 98 (1): 105-117, 1970.
1969
Jelliffe, R WCommon medical causes of headache. In J.Hosp.Dent.Pract., 3 (4): 83-85, 1969.
Jelliffe, R WAdministration of digoxin. In Dis.Chest, 56 (1): 56-60, 1969.
Jelliffe, R W; Hill, D.; Tatter, D. and Lewis, EDeath from weight-control pills. A case report with objective postmortem confirmation. In JAMA : The Journal of the American Medical Association, 208 (10): 1843-1847, 1969.
Jelliffe, R W and Stephenson, R.G.A fluorometric determination of myocardial digoxin at autopsy, with identification of digitalis leaf, digitoxin, and gitoxin. In American Journal of Clinical Pathology, 51 (3): 347-357, 1969.
Jelliffe, R. WA mathematical analysis of digitalis kinetics in patients with normal and reduced renal function. In Mathematical Biosciences, 1 (2): 305-325, 1967.doi
Jelliffe, R WAutopsy verification of suicide by digitalis. Report of a case, with successful chemical identification of digitalis glycosides in gastric contents. In American Journal of Clinical Pathology, 47 (2): 180-185, 1967.